WS #16501
Eli Lilly reported a massive Q3 beat with $24.4B in revenue and raised full-year guidance, cementing its role as the market's premier growth story. Bristol-Myers Squibb also exceeded estimates with $13.1B in revenue, driven by Eliquis, while Gen Digital gained on a beat-and-raise. This cluster signals sustained demand for weight-loss drugs and cybersecurity, providing a defensive yet high-growth anchor for the portfolio. Visa's 13% sales rise and Hyatt's 7.2% RevPAR increase highlight continued strength in travel and consumer spending. Crocs raised its full-year outlook, and Hershey beat estimates, suggesting that consumer discretionary and staples are not yet succumbing to demand destruction. This cluster counters bearish recession narratives and supports bullish positions in consumer-facing equities.
Healthcare & Pharma Earnings Dominance
Eli Lilly reported a massive Q3 beat with $24.4B in revenue and raised full-year guidance, cementing its role as the market's premier growth story. Bristol-Myers Squibb also exceeded estimates with $13.1B in revenue, driven by Eliquis, while Gen Digital gained on a beat-and-raise. This cluster signals sustained demand for weight-loss drugs and cybersecurity, providing a defensive yet high-growth anchor for the portfolio.
Visa's 13% sales rise and Hyatt's 7.2% RevPAR increase highlight continued strength in travel and consumer spending. Crocs raised its full-year outlook, and Hershey beat estimates, suggesting that consumer discretionary and staples are not yet succumbing to demand destruction. This cluster counters bearish recession narratives and supports bullish positions in consumer-facing equities.